STI testing and diagnosis rates among patients with Mpox in 2 populous US cities, 2022.

IF 8.3 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

BMC Medicine Pub Date : 2025-10-09 DOI:10.1186/s12916-025-04396-1

Shauna H Gunaratne, Karen J Vigil, Simian Huang, Nina Kumenda, Jacob McLean, Clare DeLaurentis, Delivette Castor, Jason Zucker

{"title":"STI testing and diagnosis rates among patients with Mpox in 2 populous US cities, 2022.","authors":"Shauna H Gunaratne, Karen J Vigil, Simian Huang, Nina Kumenda, Jacob McLean, Clare DeLaurentis, Delivette Castor, Jason Zucker","doi":"10.1186/s12916-025-04396-1","DOIUrl":null,"url":null,"abstract":"Background: Mpox is recognized as a sexually transmitted infection, and the 2022 epidemic and 2024 resurgence of mpox cases through sexual transmission highlighted the need for sexually transmitted infection (STI) testing. Our objective was to observe rates of STI testing and STI diagnoses in patients with confirmed mpox in Houston, Texas and New York City, New York (NY).Methods: This was a retrospective cohort study involving manual review of confirmed mpox cases at three large clinical centers in Houston, Texas and New York City, NY. Descriptive statistics were calculated for rates of STI testing and new diagnoses of syphilis, chlamydia and gonorrhea.Results: There were 404 patients in the cohort from the three different clinical sites. The median age was 33 years. 66% underwent STI testing within two weeks of their mpox diagnosis. Among those who were tested, there were 71 patients with a new STI. Syphilis was the most newly diagnosed STI with 31 new cases. Most of the chlamydia and gonorrhea cases were extragenital (81%). Rates of chlamydia and gonorrhea tended to be higher in patients reporting site-specific symptoms (ex. pharyngitis, urethritis) than in asymptomatic patients. However, rates of STI testing were still low even in patients reporting site-specific symptoms. 63.6% of those reporting urinary symptoms, 51.9% of those reporting rectal symptoms and 47.4% reporting pharyngitis symptoms were tested for site-specific chlamydia and gonorrhea.Conclusions: Our findings highlight a gap in STI testing even in patients at high risk presenting with mpox, a sexually transmitted infection.","PeriodicalId":9188,"journal":{"name":"BMC Medicine","volume":"23 1","pages":"548"},"PeriodicalIF":8.3000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12512326/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12916-025-04396-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Mpox is recognized as a sexually transmitted infection, and the 2022 epidemic and 2024 resurgence of mpox cases through sexual transmission highlighted the need for sexually transmitted infection (STI) testing. Our objective was to observe rates of STI testing and STI diagnoses in patients with confirmed mpox in Houston, Texas and New York City, New York (NY).

Methods: This was a retrospective cohort study involving manual review of confirmed mpox cases at three large clinical centers in Houston, Texas and New York City, NY. Descriptive statistics were calculated for rates of STI testing and new diagnoses of syphilis, chlamydia and gonorrhea.

Results: There were 404 patients in the cohort from the three different clinical sites. The median age was 33 years. 66% underwent STI testing within two weeks of their mpox diagnosis. Among those who were tested, there were 71 patients with a new STI. Syphilis was the most newly diagnosed STI with 31 new cases. Most of the chlamydia and gonorrhea cases were extragenital (81%). Rates of chlamydia and gonorrhea tended to be higher in patients reporting site-specific symptoms (ex. pharyngitis, urethritis) than in asymptomatic patients. However, rates of STI testing were still low even in patients reporting site-specific symptoms. 63.6% of those reporting urinary symptoms, 51.9% of those reporting rectal symptoms and 47.4% reporting pharyngitis symptoms were tested for site-specific chlamydia and gonorrhea.

Conclusions: Our findings highlight a gap in STI testing even in patients at high risk presenting with mpox, a sexually transmitted infection.

查看原文本刊更多论文

2022年美国两个人口稠密城市m痘患者的性传播感染检测和诊断率。

背景：m痘被认为是一种性传播感染，2022年的流行和2024年通过性传播再次出现的m痘病例突出了对性传播感染（STI）进行检测的必要性。我们的目的是观察德克萨斯州休斯顿和纽约州纽约市确诊的麻疹患者的性传播感染检测率和性传播感染诊出率。方法：这是一项回顾性队列研究，涉及在德克萨斯州休斯顿和纽约州纽约市的三个大型临床中心对确诊的m痘病例进行人工审查。描述性统计计算了性传播感染检测率和梅毒、衣原体和淋病新诊断率。结果：该队列中有404例患者来自三个不同的临床站点。平均年龄为33岁。66%的人在确诊后两周内接受了性传播感染检测。在接受检测的人中，有71名患者感染了新的性传播感染。梅毒是最多的新发性病，有31例新发病例。大多数衣原体和淋病病例发生在生殖器外（81%）。衣原体和淋病的发病率在报告部位特异性症状（如咽炎、尿道炎）的患者中往往高于无症状患者。然而，即使在报告特定部位症状的患者中，性传播感染检测率仍然很低。63.6%报告泌尿系统症状的患者、51.9%报告直肠症状的患者和47.4%报告咽炎症状的患者接受了部位特异性衣原体和淋病检测。结论：我们的研究结果强调了在性传播感染m痘高危患者中进行性传播感染检测的差距。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Medicine 医学-医学：内科

CiteScore

13.10

自引率

1.10%

发文量

435

审稿时长

4-8 weeks

期刊介绍： BMC Medicine is an open access, transparent peer-reviewed general medical journal. It is the flagship journal of the BMC series and publishes outstanding and influential research in various areas including clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities. In addition to research articles, the journal also publishes stimulating debates, reviews, unique forum articles, and concise tutorials. All articles published in BMC Medicine are included in various databases such as Biological Abstracts, BIOSIS, CAS, Citebase, Current contents, DOAJ, Embase, MEDLINE, PubMed, Science Citation Index Expanded, OAIster, SCImago, Scopus, SOCOLAR, and Zetoc.